Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1902 1
1903 1
1909 1
1910 1
1911 2
1912 1
1913 1
1914 1
1918 1
1923 1
1924 1
1927 1
1928 1
1929 1
1930 2
1931 1
1932 1
1934 2
1935 3
1936 1
1938 1
1939 1
1940 1
1941 1
1945 2
1947 4
1949 5
1950 5
1951 1
1952 3
1953 8
1954 2
1956 3
1957 2
1958 2
1959 1
1960 2
1962 3
1963 3
1964 1
1965 4
1966 1
1967 3
1968 6
1969 3
1970 5
1971 5
1972 1
1973 3
1974 1
1975 3
1976 3
1977 2
1978 2
1979 2
1980 2
1981 1
1982 4
1983 3
1984 2
1985 11
1986 11
1987 19
1988 18
1989 10
1990 19
1991 11
1992 7
1993 10
1994 11
1995 9
1996 7
1997 7
1998 12
1999 15
2000 17
2001 35
2002 21
2003 17
2004 12
2005 30
2006 18
2007 28
2008 22
2009 27
2010 25
2011 36
2012 24
2013 22
2014 23
2015 22
2016 26
2017 22
2018 28
2019 32
2020 28
2021 32
2022 23
Text availability
Article attribute
Article type
Publication date

Search Results

834 results
Results by year
Filters applied: . Clear all
Page 1
Vaccine Therapies for Cancer: Then and Now.
Morse MA, Gwin WR 3rd, Mitchell DA. Morse MA, et al. Target Oncol. 2021 Mar;16(2):121-152. doi: 10.1007/s11523-020-00788-w. Epub 2021 Jan 29. Target Oncol. 2021. PMID: 33512679 Free PMC article. Review.
The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS. Morse MA, et al. Clin Cancer Res. 2019 Feb 1;25(3):912-920. doi: 10.1158/1078-0432.CCR-18-1254. Epub 2018 Oct 1. Clin Cancer Res. 2019. PMID: 30274981 Review.
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.
Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, Sawyer MB, Hendlisz A, Neyns B, Svrcek M, Moss RA, Ledeine JM, Cao ZA, Kamble S, Kopetz S, André T. Overman MJ, et al. Among authors: morse ma. J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20. J Clin Oncol. 2018. PMID: 29355075 Free article.
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.
Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, Goldberg MV, Cao ZA, Ledeine JM, Maglinte GA, Kopetz S, André T. Overman MJ, et al. Among authors: morse ma. Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Lancet Oncol. 2017. PMID: 28734759 Free PMC article. Clinical Trial.
DC-CIK as a widely applicable cancer immunotherapy.
Wang S, Wang X, Zhou X, Lyerly HK, Morse MA, Ren J. Wang S, et al. Among authors: morse ma. Expert Opin Biol Ther. 2020 Jun;20(6):601-607. doi: 10.1080/14712598.2020.1728250. Epub 2020 Feb 13. Expert Opin Biol Ther. 2020. PMID: 32033522 Review.
Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
Sharma P, Siefker-Radtke A, de Braud F, Basso U, Calvo E, Bono P, Morse MA, Ascierto PA, Lopez-Martin J, Brossart P, Rohrberg K, Mellado B, Fischer BS, Meadows-Shropshire S, Abdel Saci, Callahan MK, Rosenberg J. Sharma P, et al. Among authors: morse ma. J Clin Oncol. 2019 Jul 1;37(19):1608-1616. doi: 10.1200/JCO.19.00538. Epub 2019 May 17. J Clin Oncol. 2019. PMID: 31100038 Free PMC article. Clinical Trial.
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.
Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, Morse MA, Ascierto PA, Horn L, Amin A, Pillai RN, Evans J, Chau I, Bono P, Atmaca A, Sharma P, Harbison CT, Lin CS, Christensen O, Calvo E. Antonia SJ, et al. Among authors: morse ma. Lancet Oncol. 2016 Jul;17(7):883-895. doi: 10.1016/S1470-2045(16)30098-5. Epub 2016 Jun 4. Lancet Oncol. 2016. PMID: 27269741 Free article. Clinical Trial.
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer.
Strickler JH, Rushing CN, Uronis HE, Morse MA, Niedzwiecki D, Blobe GC, Moyer AN, Bolch E, Webb R, Haley S, Hatch AJ, Altomare IP, Sherrill GB, Chang DZ, Wells JL, Hsu SD, Jia J, Zafar SY, Nixon AB, Hurwitz HI. Strickler JH, et al. Among authors: morse ma. Oncologist. 2021 Jun;26(6):465-e917. doi: 10.1002/onco.13678. Epub 2021 Feb 9. Oncologist. 2021. PMID: 33469991 Free PMC article. Clinical Trial.
834 results